Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part A and C:
Overtly healthy as determined by medical evaluation
Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
Male participants who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in part A and C
Part B:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
18 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal